Skip to main content
    T

    Treace Medical Concepts Inc (TMCI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.42
    -0.85 (-16.13%)

    Market Cap: $345.50M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Treace Medical Concepts Inc (TMCI) Earnings: Report Dates and Results

    Updated Nov 6, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Treace Medical Concepts (TMCI) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, Treace Medical Concepts reported EPS of -$0.19, above the -$0.26 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(16/22)
    Avg Surprise
    +13.69%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.08
    Range-$0.11 - -$0.05
    7 analysts
    Revenue Consensus
    $68.61M
    Range$65.56M - $71.40M
    7 analysts
    Reports May 6, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.26
    Range-$0.27 - -$0.26
    3 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.25-7.5%
    60d ago-$0.25-7.5%
    30d ago-$0.25-7.5%
    7d ago-$0.25-7.5%
    Current-$0.26
    Revenue Consensus
    $50.80M
    Range$50.40M - $51.00M
    3 analysts

    Next Report

    TMCI has an expected report date of Feb 25, 2027.

    TMCI Earnings Call

    The latest TMCI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 22 quarters below that had an estimate, TMCI beat 16, missed 5 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $48.25M, down 3.9% from $50.21M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.19-$0.26N/A+26.92%BeatN/A10 up, 1 downNov 6, 2026$48.25M
    Jun 30, 2026-$0.24-$0.30-$0.30 - -$0.30+20.00%BeatN/A10 up, 1 downAug 7, 2026$45.38M
    Mar 31, 2026-$0.28-$0.31-$0.31 - -$0.31+9.68%BeatN/A10 up, 1 downMay 8, 2026$47.20M
    Dec 31, 2025-$0.08-$0.15N/A+48.52%BeatN/A12 up, 0 downFeb 27, 2026$62.52M
    Sep 30, 2025-$0.22-$0.27-$0.28 - -$0.26+18.52%BeatN/A30 up, 3 downNov 6, 2025$50.21M
    Jun 30, 2025-$0.28-$0.29-$0.31 - -$0.26+3.45%BeatN/A30 up, 2 downAug 7, 2025$47.39M
    Mar 31, 2025-$0.25-$0.30-$0.33 - -$0.28+16.67%BeatN/A31 up, 0 downMay 8, 2025$52.57M
    Dec 31, 2024$0.00-$0.04-$0.07 - -$0.02+96.25%BeatN/A40 up, 3 downFeb 27, 2025$68.71M
    Sep 30, 2024-$0.25-$0.26-$0.30 - -$0.25+3.85%BeatN/A60 up, 0 downNov 5, 2024$45.09M
    Jun 30, 2024-$0.28-$0.28-$0.32 - -$0.260.00%In lineN/A70 up, 0 downAug 6, 2024$44.45M
    Mar 31, 2024-$0.28-$0.31-$0.37 - -$0.27+9.68%BeatN/A70 up, 0 downMay 7, 2024$51.11M
    Dec 31, 2023-$0.10-$0.09-$0.15 - -$0.04-11.11%MissN/A70 up, 0 downFeb 27, 2024$62.21M
    Sep 30, 2023-$0.28-$0.26-$0.31 - -$0.24-7.69%MissN/A70 up, 1 downNov 9, 2023$40.76M
    Jun 30, 2023-$0.20-$0.23-$0.27 - -$0.19+13.04%BeatN/A60 up, 0 downAug 8, 2023$41.95M
    Mar 31, 2023-$0.23-$0.24-$0.29 - -$0.19+4.17%BeatN/A60 up, 0 downMay 8, 2023$42.20M
    Dec 31, 2022-$0.08-$0.14-$0.17 - -$0.11+42.86%BeatN/A40 up, 0 downMar 7, 2023$49.77M
    Sep 30, 2022-$0.22-$0.29-$0.30 - -$0.28+24.14%BeatN/A40 up, 0 downNov 8, 2022$33.05M
    Jun 30, 2022-$0.23-$0.19-$0.24 - -$0.18-21.05%MissN/A40 up, 0 downAug 9, 2022$29.97M
    Mar 31, 2022-$0.16-$0.17-$0.25 - -$0.14+5.88%BeatN/A40 up, 0 downMay 5, 2022$29.05M
    Dec 31, 2021-$0.12-$0.01-$0.01 - $0.00N/AN/A-300.0%4N/AMar 3, 2022$33.44M
    Sep 30, 2021-$0.12-$0.11-$0.13 - -$0.11-9.09%MissN/A40 up, 0 downNov 4, 2021$21.62M
    Jun 30, 2021-$0.10-$0.13-$0.15 - -$0.10+23.08%BeatN/A4N/AAug 5, 2021$20.65M
    Mar 31, 2021-$0.07-$0.06N/A-16.67%MissN/AN/AN/AApr 26, 2021$18.71M
    Dec 31, 2020$0.06N/AN/AN/AN/AN/AN/AN/AMar 3, 2021$24.10M
    Dec 31, 2019-$0.05N/AN/AN/AN/AN/AN/AN/AMar 30, 2020N/A
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.83, after -$0.81 the year before. It was -$0.05 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.83N/A
    Dec 31, 2024-$0.81N/A
    Dec 31, 2023-$0.81N/A
    Dec 31, 2022-$0.69N/A
    Dec 31, 2021-$0.41-783.3%
    Dec 31, 2020$0.06N/A
    Dec 31, 2019-$0.05N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,7228
    2026Q2Jun 30, 20265,0109
    2026Q1Mar 31, 20265,0698
    2025Q4Dec 31, 20256,68310
    2025Q3Sep 30, 20253,6496
    2025Q2Jun 30, 20253,8918
    2025Q1Mar 31, 20254,1547
    2024Q4Dec 31, 20245,81410

    2026Q3 Earnings Call

    Opening remarks

    Trip Taylor Investor Relations Good morning, everyone, and welcome to our third quarter 2026 earnings conference call. Participating from the company today will be John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer. John and Mark will discuss our third quarter financial results and our 2026 outlook. We will then host a question-and-answer session following our prepared remarks. Our press release can be found in the Investor Relations section of our website at investors.treace.com. This call is being recorded and will be archived in the Investor Relations section of our website. Before we begin, we would like to remind you that it is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 2000. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon currently available information, and Treace Medical assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. Please refer to our SEC filings, including our 2025 Form 10-K and our Form 10-Q for the third quarter of 2026, filed before the market opened today, November 6, which can be found in the Investor Relations section of our website at investors.treace.com, for a detailed presentation of risks. With that, I will now turn the call over to John. Thank you, Trip.

    John T. Treace CEO Good morning, everyone, and thank you for joining us on our third quarter 2026 earnings conference call. We are encouraged by our third quarter performance, driven by double-digit case volume growth and continued market share gains from increasing adoption of our comprehensive portfolio of best-in-class bunion systems and our expanding line of new technologies. During the quarter, we continued to advance our strategic priorities with investments in new products, creating opportunities to build on the foundation that Lapiplasty has established as our surgeon customers adopt more of our new products into their practices. As we expand our presence across a broader range of foot and ankle procedures, we expect the new 2026 product introductions that I will discuss this morning to expand our total addressable market by approximately $700 million. This strategy has allowed us to leverage our commercial resources to pursue high-impact growth opportunities while maintaining disciplined expense management. We believe this approach positions us to enhance our growth trajectory while improving operating performance over time.

    Frequently Asked Questions About TMCI

    When is Treace Medical Concepts's next earnings date?

    Treace Medical Concepts's next earnings report is expected for Feb 25, 2027.

    Did TMCI beat earnings estimates last quarter?

    Yes. Treace Medical Concepts reported EPS of -$0.19 for the quarter ended Sep 30, 2026, above the -$0.26 estimate, a 26.92% surprise.

    What EPS do analysts expect from TMCI next quarter?

    The consensus EPS estimate for Treace Medical Concepts for the quarter ending Dec 31, 2026 is -$0.08 from 7 analysts, with estimates from -$0.11 to -$0.05.

    How often does TMCI beat earnings estimates?

    Treace Medical Concepts beat the EPS estimate in each of the last 9 quarters, with an average surprise of +27.09%.